The influence of repeated doses, route and time of administration on the neuroprotective effects of BIII 277 CL in a rat model of focal cerebral ischemia

Journal of Stroke and Cerebrovascular Diseases

Volumn 6, Issue 2, 1996, Pages 93-99

  Pschorn, Uwe ^a   Carter, Adrian J ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

BIII 277 CL; Focal ischemia; Middle cerebral artery occlusion; Neuroprotection; Noncompetitive NMDA antagonist

Indexed keywords

EID: 0342315207     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-3057(96)80010-3     Document Type: Article

References (53)

1. Bonita R. Epidemiology of stroke. Lancet 339 (1992) 342-344
2. Chopp M., and Zhang R.L. Animal modeling for developing stroke therapy. In: Fisher M. (Ed). Stroke Therapy (1995), Butterworth-Heinemann, Boston 117-134
3. Bamford J. Clinical examination in diagnosis and subclassification of stroke. Lancet 339 (1992) 400-402
4. Ginsberg M.D., and Busto R. Rodent models of cerebral ischemia. Stroke 20 (1989) 1627-1642
5. Macrae I.M. New models of focal cerebral ischaemia. Br J Clin Pharmacol 34 (1992) 302-308
6. Hunter A.J., Green A.R., and Cross A.J. Animal models of acute stroke: can they predict clinically successful neuroprotective drugs?. Trends Pharmacol Sci 16 (1995) 123-128
7. Grotta J. The current status of neuronal protective therapy: why have all neuronal protective drugs worked in animals but none so far in stroke patients. Cerebrovasc Dis 4 (1994) 115-120
8. Rothman S.M. Synaptic activity mediates death of hypoxic neurons. Science 220 (1983) 536-537
9. Rothman S.M. Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. J Neurosci 4 (1984) 1884-1891
10. Benveniste H., Drejer J., Schousboe A., and Diemer N.H. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 43 (1984) 1369-1374
11. Butcher S.T.P., Bullock R., Graham D.I., and McCulloch J. Correlation between amino acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion. Stroke 21 (1990) 1727-1733
12. Simon R.P., Swan J.H., Griffiths T., and Meldrum B.S. Blockade of N-methyl-d-aspartate receptors may protect against ischemic damage in the brain. Science 226 (1984) 850-852
13. Ozyurt E., Graham D.I., Woodruff G.N., and McCulloch J. Protective effect of the glutamate antagonist, MK-801 in focal cerebral ischemia. J Cereb Blood Flow Metab 8 (1988) 128-143
14. Park C.K., Nehls D.G., Graham D.I., Teasdale G.M., and McCulloch J. The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann Neurol 24 (1988) 543-551
15. Sheardown M.J., Nielsen E.O., Hansen A.J., Jacobsen P., and Honoré T. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F) quinoxaline: a neuroprotectant for cerebral ischemia. Science 247 (1990) 571-574
16. Buchan A.M., Li H., Cho S., and Pulsinelli W.A. Blockade of the AMPA receptor prevents CA1 hippocampal injury following severe but transient forebrain ischemia in adult rats. Neurosci Lett 132 (1991) 255-258
17. Gill R., Nordholm L., and Lodge D. The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) in a rat focal ischaemia model. Brain Res 580 (1992) 35-43
18. Reynolds I.J., and Miller R.J. Multiples sites for the regulation of the N-methyl-d-aspartate receptor. Mol Pharmacol 33 (1988) 581-584
19. Watkins J.C., Krogsgaard-Larsen P., and Honoré T. Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol Sci 11 (1990) 25-33
20. Carter A.J. Glycine antagonists: regulation of the NMDA receptor-channel complex by the strychnine-insensitive glycine site. Drugs Future 17 (1992) 595-613
21. Foster A.C. Channel blocking drugs for the NMDA receptor. In: Meldrum B.S. (Ed). Excitatory Amino Acid Antagonists (1991), Blackwell, Oxford, England 164-179
22. Anis N.A., Berry S.C., Burton N.R., and Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurons by N-methyl-d-aspartate. Br J Pharmacol 79 (1983) 565-575
23. Wong E., Kemp J.A., Priestley T., Knight A.R., Woodruff G.N., and Iversen L.L. The anticonvulsant MK-801 is a potent N-methyl-d-aspartate antagonist. Proc Natl Acad Sci USA 83 (1986) 7104-7108
24. Reddy N.L., Hu L.-Y., Cotter R.E., et al. Synthesis and structure-activity studies of N,N′-diarylguanidine derivatives. N-(1-naphthyl)-N′-(3-ethylphenyl)-N′-methylguanidine: a new, selective noncompetitive NMDA receptor antagonist. J Med Chem 37 (1994) 260-267
25. Carter A.J., Bechtel W.D., Grauert M., Harrison P., Merz H., and Stransky W. BIII 277 CL is a potent and specific ionchannel blocker of the NMDA receptor-channel complex. J Pharmacol Exp Ther 275 (1995) 1382-1389
26. Grauert M., Rho J.M., and Rogawski M.A. BIII 277 CL and BIII 281, two enantiomeric NMDA open-channel blockers: electrophysiological characterization. Soc Neurosci Abstr 21 (1995) 1105
27. Tamura A., Graham D.I., McCulloch J., and Teasdale G.M. Focal cerebral ischaemia in the rat: I. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. J Cereb Blood Flow Metab 1 (1981) 53-60
28. Bielenberg G.W., and Beck T. The effects of dizocilpine (MK-801), phencyclidine, and nimodipine on infarct size 48 h after middle cerebral artery occlusion in the rat. Brain Res 552 (1991) 338-342
29. Roussel S., Pinard E., and Seylaz J. Effect of MK-801 on focal brain infarction in normotensive and hypertensive rats. Hypertension 19 (1992) 40-46
30. Iijima T., Mies G., and Hossmann K.-A. Repeated negative DC deflections in rat cortex following middle cerebral artery occlusion are abolished by MK-801: effect on volume of ischemic injury. J Cereb Blood Flow Metab 12 (1992) 727-733
31. Hatfield R.H., Gill R., and Brazell C. The dose-response relation-ship and therapeutic window for dizocilpine (MK-801) in a rat focal ischaemia model. Eur J Pharmacol 216 (1992) 1-7
32. Dirnagl U., Tanabe J., and Pulsinelli W. Pre- and post-treatment with MK 801 but not pretreatment alone reduces neocortical damage after focal cerebral ischemia in the rat. Brain Res 527 (1990) 62-68
33. Buchan A.M., Slivka A., and Xue D. The effect of the NMDA receptor antagonist MK-801 on cerebral blood flow and infarct volume in experimental focal stroke. Brain Res 574 (1992) 171-177
34. Lo E.H., Matsumoto K., Pierce A.R., Garrido L., and Luttinger D. Pharmacologic reversal of acute changes in diffusion-weighted magnetic resonance imaging in focal cerebral ischemia. J Cereb Blood Flow Metab 14 (1994) 597-603
35. Sauer D., Allegrini P.R., Cosenti A., Pataki A., Amacker H., and Fagg G.E. Characterization of the cerebroprotective efficacy of the competitive NMDA receptor antagonist CGP40116 in a rat model of focal cerebral ischemia: an in vivo magnetic resonance imaging study. J Cereb Blood Flow Metab 13 (1993) 595-602
36. Jaffe J.H., and Martin W.R. Opioid analgesics and antagonists. In: Goodman A.G., Rall T.W., Nies A.S., and Taylor P. (Eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics (1995), McGraw-Hill, New York 485-521
37. Graham S.H., Chen J., and Simon R.P. A dose-response study of dextrorphan in permanent focal ischemia. Neurosci Lett 160 (1993) 21-23
38. Carter A.J. Many agents that antagonize the NMDA receptor-channel complex in vivo also cause disturbances of motor coordination. J Pharmacol Exp Ther 269 (1994) 573-580
39. Minematsu K., Fisher M., Li L., et al. Effects of a novel NMDA antagonist on experimental stroke rapidly and quantitatively assessed by diffusion-weighted MRI. Neurology 43 (1993) 397-403
40. Aronowski J., Ostrow P., Samways E., Strong R., Zivin J.A., and Grotta J.C. Graded bioassay for demonstration of brain rescue from experimental acute ischemia in rats. Stroke 25 (1994) 2235-2240
41. Hasegawa Y., Latour L.L., Sotak C.H., Dardzinski B.J., and Fisher M. Temperature dependent change of a apparent diffusion coefficient of water in normal and ischemic brain of rats. J Cereb Blood Flow Metab 14 (1994) 383-390
42. Meadows M.-E., Fisher M., and Minematsu K. Delayed treatment with a noncompetitive NMDA antagonist, CNS-1102, reduces infarct size in rats. Cerebrovasc Dis 4 (1994) 26-31
43. Pulsinelli W. Pathophysiology of acute ischaemic stroke. Lancet 339 (1992) 533-536
44. Wityk R.J., and Stern B.J. Ischemic stroke: today and tomorrow. Crit Care Med 22 (1994) 1278-1293
45. Albers G.W., Goldberg M.P., and Choi D.W. N-Methyl-d-aspartate antagonists: ready for clinical trial in brain ischemia. Ann Neurol 25 (1989) 398-403
46. Albers G.W. Potential therapeutics uses of N-methyl-d-aspartate antagonists in cerebral ischemia. Clin Neuropharmacol 13 (1990) 177-197
47. Krystal J.H., Karper L.P., Seibyl J.P., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51 (1994) 199-214
48. Muir K.W., Grosset D.G., Gamzu E., and Lees K.R. Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers. Br J Clin Pharmacol 38 (1994) 33-38
49. Albers G.W., Atkinson R.P., Kelley R.E., and Rosenbaum D.M. Safety, tolerability, and pharmacokinetics of the N-methyl-d-aspartate antagonist dextrorphan in patients with acute stroke. Stroke 26 (1995) 254-258
50. Grotta J., Clark W., Coull B., et al. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke: results of a phase IIa randomized trial. Stroke 26 (1995) 602-605
51. Muir K.W., and Lees K.R. Clinical experience with excitatory amino acid antagonist drugs. Stroke 26 (1995) 503-513
52. Carter A.J. Antagonists of the NMDA receptor-channel complex and motor coordination. Life Sci 57 (1995) 917-929
53. McIntosh B. The rat brain (1995), Neurographics, Inc., Ontario, Canada